Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 juil. 2019 11h03 HE | Source: Asklepion Pharmaceuticals, LLC.

Asklepion Pharmaceuticals concludes enrollment of Phase III trial: L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects

BALTIMORE, July 01, 2019 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare...
26 avr. 2019 09h42 HE | Source: Asklepion Pharmaceuticals, LLC.

Key Patent Coverage for Asklepion Pharmaceuticals’ Investigational Candidate Extended to 2036

BALTIMORE, April 26, 2019 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare...
19 déc. 2017 09h00 HE | Source: Asklepion Pharmaceuticals, LLC.

Asklepion Pharmaceuticals Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Program of Intravenous Citrulline

BALTIMORE, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”) announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA)...
08 déc. 2017 09h00 HE | Source: Asklepion Pharmaceuticals, LLC.

Asklepion Pharmaceuticals Presents Phase 1b/2a Clinical Trial Data for IV-Citrulline at the Pediatric Cardiac Intensive Care Society 13th Annual International Meeting

BALTIMORE, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of IV-citrulline for rare pediatric...